Research Article
No access
Published Online: 1 October 2017

Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells

Publication: Human Gene Therapy
Volume 28, Issue Number 10

Abstract

The administration of ex vivo expanded natural killer (NK) cells as potential antitumor effector cells appears to be suitable for effector cell-based immunotherapies in high-risk cancer patients. However, good manufacturing practice (GMP)-compliant manufacturing of clinical-grade NK cells at sufficiently high numbers represents a great challenge. Therefore, previous expansion protocols for those effector cells were improved and optimized by using newly developed culture medium, interleukin (IL)-21, and autologous feeder cells (FCs). Separation of primary human NK cells (CD56+CD3) was carried out with the CliniMACS Prodigy® in a single process, starting with approximately 1.2 × 109 leukocytes collected by small-scale lymphapheresis or from buffy coats. Enriched NK cells were adjusted to starting cell concentrations within approximately 1 × 106 effector cells/mL and cultured in comparative expansion experiments for 14 days with IL-2 (1,000 IU/mL) in different GMP-compliant media (X-VIVO10, CellGro®, TexMACS, and NK MACS®). After medium optimization, beneficial effects for functionality and phenotype were investigated at the beginning of cell expansion with irradiated (25 Gy) autologous FCs at a ratio of 20:1 (feeder: NK) in the presence or absence of IL-21 (100 ng/mL). Additionally, expanded NK cells were gene modified to express chimeric antigen receptors (CARs) against CD123, a common marker for acute myeloid leukemia (AML). Cytotoxicity, degranulation, and cytokine release of transduced NK cells were determined against KG1a cells in flow cytometric analysis and fluorescent imaging. The Prodigy manufacturing process revealed high target cell viabilities (median 95.4%), adequate NK cell recovery (median 60.4%), and purity of 95.4% in regard to CD56+CD3- target cells. The process in its early phase of development led to a median T-cell depletion of log 3.5 after CD3 depletion and log 3.6 after the whole process, including CD3 depletion and CD56 enrichment steps. Manually performed experiments to test different culture media demonstrated significantly higher NK cell expansion rates and an approximately equal distribution of CD56dimCD16pos and CD56brightCD16dim&neg NK subsets on day 14 with cells cultivated in NK MACS® media. Moreover, effector cell expansion in manually performed experiments with NK MACS® containing IL-2 and irradiated autologous FCs and IL-21, both added at the initiation of the culture, induced an 85-fold NK cell expansion. Compared to freshly isolated NK cells, expanded NK cells expressed significantly higher levels of NKp30, NKp44, NKG2D, TRAIL, FasL, CD69, and CD137, and showed comparable cell viabilities and killing/degranulation activities against tumor and leukemic cell lines in vitro. NK cells used for CAR transduction showed the highest anti-CD123 CAR expression on day 3 after gene modification. These anti-CD123 CAR-engineered NK cells demonstrated improved cytotoxicity against the CD123pos AML cell line KG1a and primary AML blasts. In addition, CAR NK cells showed higher degranulation and enhanced secretion of tumor necrosis factor alpha, interferon gamma, and granzyme A and B. In fluorescence imaging, specific interactions that initiated apoptotic processes in the AML target cells were detected between CAR NK cells and KG1a. After the fully automated NK cell separation process on Prodigy, a new NK cell expansion protocol was generated that resulted in high numbers of NK cells with potent antitumor activity, which could be modified efficiently by novel third-generation, alpha-retroviral SIN vector constructs. Next steps are the integration of the manual expansion procedure in the fully integrated platform for a standardized GMP-compliant overall process in this closed system that also may include gene modification of NK cells to optimize target-specific antitumor activity.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program 2013;2013:234–246.
2.
Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008;9:503–510.
3.
Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 2015;6:578.
4.
Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197–223.
5.
Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006;6:940–952.
6.
Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005;42:501–510.
7.
Koehl U, Brehm C, Huenecke S, et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol 2013;3:118.
8.
Ahn YO, Kim S, Kim TM, et al. Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro. J Immunother 2013;36:373–381.
9.
Kim EK, Ahn YO, Kim S, et al. Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers. Cytotherapy 2013;15:231–241.
10.
Delso-Vallejo M, Kollet J, Koehl U, et al. Influence of irradiated peripheral blood mononuclear cells on both ex vivo proliferation of human natural killer calls and change in cellular property. Front Immunol 2017;8:854.
11.
Lim O, Lee Y, Chung H, et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS One 2013;8:e53611.
12.
Granzin M, Stojanovic A, Miller M, et al. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology 2016;5:e1219007.
13.
Huenecke S, Zimmermann SY, Kloess S, et al. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 2010;33:200–210.
14.
Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005;86:209–239.
15.
Mao Y, van Hoef V, Zhang X, et al. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood 2016;128:1475–1489.
16.
van Ostaijen-ten Dam MM, Prins HJ, Boerman GH, et al. Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential. J Immunother 2016;39:90–100.
17.
Torelli GF, Rozera C, Santodonato L, et al. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use. Blood Transfus 2015;13:464–471.
18.
Iannello A, Boulassel MR, Samarani S, et al. IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication. J Leukoc Biol 2010;87:857–867.
19.
McMichael EL, Jaime-Ramirez AC, Guenterberg KD, et al. IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells. Clin Cancer Res 2017;23:489–502.
20.
Kloess S, Huenecke S, Piechulek D, et al. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol 2010;40:3255–3267.
21.
Oberschmidt O, Kloess S, Koehl U. Redirected primary human chimeric antigen receptor natural killer cells as an “off-the-shelf immunotherapy” for improvement in cancer treatment. Front Immunol 2017;8:654.
22.
Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014;28:1596–1605.
23.
Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001;86:1261–1269.
24.
Koehl U, Kalberer C, Spanholtz J, et al. Advances in clinical NK cell studies: donor selection, manufacturing and quality control. Oncoimmunology 2016;5:e1115178.
25.
Suerth JD, Morgan MA, Kloess S, et al. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. J Mol Med (Berl) 2016;94:83–93.
26.
Suerth JD, Maetzig T, Galla M, et al. Self-inactivating alpharetroviral vectors with a split-packaging design. J Virol 2010;84:6626–6635.
27.
Hubner J, Hoseini SS, Suerth JD, et al. Generation of genetically engineered precursor T-cells from human umbilical cord blood using an optimized alpharetroviral vector platform. Mol Ther 2016;24:1216–1226.
28.
Berg M, Lundqvist A, McCoy P Jr, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009;11:341–355.
29.
Barros LF, Kanaseki T, Sabirov R, et al. Apoptotic and necrotic blebs in epithelial cells display similar neck diameters but different kinase dependency. Cell Death Differ 2003;10:687–697.
30.
Siegler U, Meyer-Monard S, Jorger S, et al. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010;12:750–763.
31.
Granzin M, Soltenborn S, Muller S, et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 2015;17:621–632.
32.
Parkhurst MR, Riley JP, Dudley ME, et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011;17:6287–6297.
33.
Davis MR, Zhu Z, Hansen DM, et al. The role of IL-21 in immunity and cancer. Cancer Lett 2015;358:107–114.
34.
Wendt K, Wilk E, Buyny S, et al. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007;122:486–495.
35.
Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 2014;20:696–704.
36.
Rabinowich H, Sedlmayr P, Herberman RB, et al. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol 1991;135:454–470.
37.
Bae DS, Lee JK. Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line. Blood Res 2014;49:154–161.
38.
Warren HS, Kinnear BF, Skipsey LJ. Human natural killer (NK) cells: requirements for cell proliferation and expansion of phenotypically novel subpopulations. Immunol Cell Biol 1993;71:87–97.
39.
Lim SA, Kim TJ, Lee JE, et al. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res 2013;73:2598–2607.
40.
Lee DA. Regulatory considerations for NK cells used in human immunotherapy applications. Methods Mol Biol 2016;1441:347–361.
41.
Suerth JD, Morgan MA, Kloess S, et al. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. J Mol Med 2016;94:83–93.
42.
Kobayashi K, Hashimoto M, Honkakoski P, et al. Regulation of gene expression by CAR: an update. Arch Toxicol 2015;89:1045–1055.
43.
Suerth JD, Labenski V, Schambach A. Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy. Viruses 2014;6:4811–4838.
44.
Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013;161:389–401.
45.
Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013;122:3138–3148.
46.
Mardiros A, Brown CE, Budde LE, et al. Acute myeloid leukemia therapeutics: CARs in the driver's seat. Oncoimmunology 2013;2:e27214.
47.
Tettamanti S, Biondi A, Biagi E, et al. CD123 AML targeting by chimeric antigen receptors: a novel magic bullet for AML therapeutics? Oncoimmunology 2014;3:e28835.

Information & Authors

Information

Published In

cover image Human Gene Therapy
Human Gene Therapy
Volume 28Issue Number 10October 2017
Pages: 897 - 913
PubMed: 28810809

History

Published in print: October 2017
Published online: 1 October 2017
Published ahead of production: 16 August 2017
Published ahead of print: 15 August 2017
Accepted: 14 August 2017
Received: 13 August 2017

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Stephan Klöß* [email protected]
Institute for Cellular Therapeutics, GMPDU, IFB-Tx, Hannover Medical School, Hannover, Germany
Olaf Oberschmidt
Institute for Cellular Therapeutics, GMPDU, IFB-Tx, Hannover Medical School, Hannover, Germany
Michael Morgan
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany
Julia Dahlke
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany
Lubomir Arseniev
Institute for Cellular Therapeutics, GMPDU, IFB-Tx, Hannover Medical School, Hannover, Germany
Volker Huppert
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
Markus Granzin
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
Tanja Gardlowski
Institute for Cellular Therapeutics, GMPDU, IFB-Tx, Hannover Medical School, Hannover, Germany
Nadine Matthies
Institute for Cellular Therapeutics, GMPDU, IFB-Tx, Hannover Medical School, Hannover, Germany
Stephanie Soltenborn
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
Axel Schambach
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Ulrike Koehl
Institute for Cellular Therapeutics, GMPDU, IFB-Tx, Hannover Medical School, Hannover, Germany

Notes

*
Correspondence: Dr. Stephan Klöß, Institute of Cellular Therapeutics, GMP Development Unit (OE 8885), IFB-Tx, Hannover Medical School (MHH), Feodor-Lynen-Str. 21, D-30625, Hannover, Germany. E-mail: [email protected]

Author Disclosure

The authors declare no financial or commercial conflicts of interest, except that A.S. is co-inventor on a patent application describing alpha-retroviral SIN vectors.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top